Stock NXS NEXT SCIENCE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Next Science Limited

Equities

NXS

AU0000041329

Delayed Australian S.E.
Other stock markets
 10:50:05 2024-05-29 pm EDT 		5-day change 1st Jan Change
0.2525 AUD -0.98% Intraday chart for Next Science Limited +1.00% -25.74%
May. 03 Transcript : Next Science Limited - Shareholder/Analyst Call
Apr. 24 Next Science Product Sales Rise 19% to $5.5 Million for March Quarter MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NEXT SCIENCE LIMITED Stock Next Science Limited
-25.74% 49.25M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.22% 731B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.57% 586B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.85% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.48% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
-0.12% 273B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.55% 235B
B+
NOVARTIS AG Stock Novartis AG
+6.65% 202B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.09% 203B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.37% 158B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NXS Stock
  4. Ratings Next Science Limited